Critical Care

Leader in Critical Care Immunotherapy

Leading the Prevention or Treatment of Life-Threatening Inflammation in the ICU and Cardiac Surgery using CytoSorb® Blood Purification

CytoSorb®, is E.U. approved, with 46,000+ treatments; distributed in 53 countries

Organ failure occurs when vital organs stop working, causing nearly half of all deaths in the ICU.

CytoSorb® targets the $20+ billion opportunity in critical care and cardiac surgery

Approved in the European Union as the first specifically approved extracorporeal cytokine adsorber

Benefits Of CytoSorbents

  • Broad indication for use where cytokines are elevated
  • Removes cytokines and many other inflammatory mediators such as free hemoglobin, bacterial toxins, myoglobin, and activated complement
  • Safe and well-tolerated: 46,000+ cumulative treatments delivered, up from 27,000 a year ago
  • Proprietary patented technology with multiple patents pending worldwide
  • Manufactured at our ISO 13485 certified facility in New Jersey
Previous Next
Test Caption
Test Description goes like this